

FIG. 1A





FIG. 1B







FIG. 2A




FIG. 2B




FIG. 2C

[illegible]

FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 3E




FIG. 4




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 6




FIG. 7A




FIG. 7A (continued)




FIG 7B

Slowing beauty IR/DR sequence

Integration junction (chr7, 79796094)

ACTTAAGTGTATGTAAACTTCCGACTTCAA

CCTAGGGTA

CCGATTCCTCCGCACTCTCTGGCCACTAGCATG

SEQ ID NO: 4

Slowing beauty IR/DR sequence

Integration junction (repeat region)

ACTTAAGTGTATGTAAACTTCCGACTTCAA

CCTGAATTT

TCGACCTTTTCAGTTTCCTCGCCATATTTCAATG

SEQ ID NO: 5

FIG. 7C

A bar chart titled 'FIG. 7C' showing the percentage distribution of various genomic features. The y-axis is labeled 'Percentage' and ranges from 0 to 100 in increments of 10. The x-axis lists seven categories. The bars are: 1Kb upstream TSS (0.0%) at 0%, 5' UTR exons (0.0%) at 0%, protein coding exons (0.0%) at 0%, Introns (17.0%) at 17%, 3'UTR(0.0%) at 0%, Downstream(0.0%) at 0%, and intergenic (83.0%) at 83%.

Genomic Feature	Percentage
1Kb upstream TSS	0.0%
5' UTR exons	0.0%
protein coding exons	0.0%
Introns	17.0%
3'UTR	0.0%
Downstream	0.0%
intergenic	83.0%

FIG. 7D




FIG. 8A

FIG. 8B





FIG. 8D




FIG. 8C




FIG. 8E




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 12A




FIG. 12B




FIG. 13




FIG. 13 (continued)




FIG. 14




FIG. 14 (continued)




FIG. 15




FIG. 16




FIG. 17




FIG. 18A




FIG. 18B




FIG. 18C

FIG. 18D





FIG. 19

Before treatment



Week 10 after treatment






FIG. 20

C57BL/6 (Normal mice)



Before treatment



Week 10 after treatment-long LCR




FIG. 21A




FIG. 21B




FIG. 21C

Bone marrow cytopins (Giemsa)




FIG. 22




FIG. 23A




FIG. 23B




FIG. 23B cont'd




FIG. 23B cont'd




FIG. 24A




FIG. 24B




FIG. 25




FIG. 26A




FIG. 26B




FIG. 26C




FIG. 27




FIG. 28




FIG. 29

no selection




FIG. 30




FIG. 31




FIG. 34




FIG. 35




FIG. 36




FIG. 37




FIG. 38

pBHCA FR IR EflaMGMT GFP (Forward HJ)




FIG. 39




FIG. 40




FIG. 41




FIG. 42




FIG. 43

PHCA(Ad5)-PT4-mgmt-GFP

32,026 bp

